{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:08:48Z","timestamp":1791662928529,"version":"4.3.4"},"reference-count":124,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:00:00Z","timestamp":1635465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Myeloid malignancies are a heterogeneous group of clonal haematopoietic disorders, caused by abnormalities in haematopoietic stem cells (HSCs) and myeloid progenitor cells that originate in the bone marrow niche. Each of these disorders are unique and present their own challenges with regards to treatment. Acute myeloid leukaemia (AML) is considered the most aggressive myeloid malignancy, only potentially curable with intensive cytotoxic chemotherapy with or without allogeneic haematopoietic stem cell transplantation. In comparison, patients diagnosed with chronic myeloid leukaemia (CML) and treated with tyrosine kinase inhibitors (TKIs) have a high rate of long-term survival. However, drug resistance and relapse are major issues in both these diseases. A growing body of evidence suggests that Interferons (IFNs) may be a useful therapy for myeloid malignancies, particularly in circumstances where patients are resistant to existing front-line therapies and have risk of relapse following haematopoietic stem cell transplant. IFNs are a major class of cytokines which are known to play an integral role in the non-specific immune response. IFN therapy has potential as a combination therapy in AML patients to reduce the impact of minimal residual disease on relapse. Alongside this, IFNs can potentially sensitize leukaemic cells to TKIs in resistant CML patients. There is evidence also that IFNs have a therapeutic role in myeloproliferative neoplasms (MPNs) such as polycythaemia vera (PV) and primary myelofibrosis (PMF), where they can restore polyclonality in patients. Novel formulations have improved the clinical effectiveness of IFNs. Low dose pegylated IFN formulations improve pharmacokinetics and improve patient tolerance to therapies, thereby minimizing the risk of haematological toxicities. Herein, we will discuss recent developments and the current understanding of the molecular and clinical implications of Type I IFNs for the treatment of myeloid malignancies.<\/jats:p>","DOI":"10.3389\/fonc.2021.769628","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T06:31:24Z","timestamp":1635489084000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["Recent Progress in Interferon Therapy for Myeloid Malignancies"],"prefix":"10.3389","volume":"11","author":[{"given":"Fiona M.","family":"Healy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lekh N.","family":"Dahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack R.E.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yngvar","family":"Floisand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Woolley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-670224","article-title":"Myeloid Malignancies and the Microenvironment","volume":"129","author":"Korn","year":"2017","journal-title":"Blood"},{"key":"B2","volume-title":"The American Cancer Society\u2019s Oncology in Practice: Clinical Management","author":"Zeidner","year":"2018"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 Revision to the World Health Organization Classification of Myeloid Neoplasms and Acute Leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1159\/000488712","article-title":"The Molecular Pathology of Myelodysplastic Syndrome","volume":"86","author":"Haferlach","year":"2019","journal-title":"Pathobiology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 Alterations in Acute Myeloid Leukemia With Complex Karyotype Correlate With Specific Copy Number Alterations, Monosomal Karyotype, and Dismal Outcome","volume":"119","author":"R\u00fccker","year":"2012","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e331 p","DOI":"10.1038\/bcj.2015.59","article-title":"TP53 Mutations in De Novo Acute Myeloid Leukemia Patients: Longitudinal Follow-Ups Show the Mutation Is Stable During Disease Evolution","volume":"5","author":"Hou","year":"2015","journal-title":"Blood Cancer J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2014.007","article-title":"Imatinib in Chronic Myeloid Leukemia: An Overview","volume":"6","author":"Sacha","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-Term Prognostic Significance of Early Molecular Response to Imatinib in Newly Diagnosed Chronic Myeloid Leukemia: An Analysis From the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00603","article-title":"Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety","volume":"9","author":"Garc\u00eda-Guti\u00e9rrez","year":"2019","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1398644","article-title":"Pharmacology and Pharmacokinetics of Imatinib in Pediatric Patients","volume":"11","author":"Suttorp","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1152\/advan.00065.2006","article-title":"A Role for Transcription Factor NF-kappaB in Autoimmunity: Possible Interactions of Genes, Sex, and the Immune Response","volume":"30","author":"Dale","year":"2006","journal-title":"Adv Physiol Educ"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0380","article-title":"Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera","volume":"21","author":"Nazha","year":"2016","journal-title":"Oncologist"},{"key":"B14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41408-018-0109-0","article-title":"Myelofibrosis Treatment Algorithm 2018","volume":"8","author":"Tefferi","year":"2018","journal-title":"Blood Cancer J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6499","article-title":"Comparative Analysis of the Value of Allogeneic Hematopoietic Stem-Cell Transplantation in Acute Myeloid Leukemia With Monosomal Karyotype Versus Other Cytogenetic Risk Categories","volume":"30","author":"Cornelissen","year":"2012","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-339721","article-title":"Outcome of Patients With Acute Myeloid Leukemia With Monosomal Karyotype Who Undergo Hematopoietic Cell Transplantation","volume":"118","author":"Fang","year":"2011","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-409813","article-title":"Detectable Minimal Residual Disease Before Hematopoietic Cell Transplantation Is Prognostic But Does Not Preclude Cure for Children With Very-High-Risk Leukemia","volume":"120","author":"Leung","year":"2012","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.173","article-title":"Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation","volume":"29","author":"Walter","year":"2015","journal-title":"Leukemia"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.9868","article-title":"Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis","volume":"30","author":"Brunet","year":"2012","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651562","article-title":"Outcome of Patients With Distinct Molecular Genotypes and Cytogenetically Normal AML After Allogeneic Transplantation","volume":"126","author":"Schmid","year":"2015","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25214","article-title":"Acute Myeloid Leukemia: 2019 Update on Risk-Stratification and Management","volume":"93","author":"Estey","year":"2018","journal-title":"Am J Hematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2016.009","article-title":"Treatment With Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) With Acute Myeloid Leukemia: A Single Institution Experience","volume":"8","author":"Heiblig","year":"2016","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax Combined With Decitabine or Azacitidine in Treatment-Naive, Elderly Patients With Acute Myeloid Leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26039","article-title":"Venetoclax With Azacitidine or Decitabine in Patients With Newly Diagnosed Acute Myeloid Leukemia: Long Term Follow-Up From a Phase 1b Study","volume":"96","author":"Pollyea","year":"2021","journal-title":"Am J Hematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.01.009","article-title":"Pretransplantation Therapy With Azacitidine vs Induction Chemotherapy and Posttransplantation Outcome in Patients With MDS","volume":"18","author":"Gerds","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04904-7","article-title":"An Overview of the Immune System","volume":"357","author":"Parkin","year":"2001","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1159\/000495897","article-title":"Type I Interferons: Distinct Biological Activities and Current Applications for Viral Infection","volume":"51","author":"Li","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"B28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.0105-2896.2004.00204.x","article-title":"Interferons, Interferon-Like Cytokines, and Their Receptors","volume":"202","author":"Pestka","year":"2004","journal-title":"Immunol Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00322","article-title":"Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-Tumor Immunity to Resistance","volume":"8","author":"Budhwani","year":"2018","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1314424","article-title":"Type-I-Interferons in Infection and Cancer: Unanticipated Dynamics With Therapeutic Implications","volume":"6","author":"Musella","year":"2017","journal-title":"Oncoimmunology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19531","article-title":"Immunomodulatory and Antitumor Effects of Type I Interferons and Their Application in Cancer Therapy","volume":"8","author":"Medrano","year":"2017","journal-title":"Oncotarget"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-20-0871","article-title":"Old Dog, New Trick: Type I IFN-Based Treatment for Acute Myeloid Leukemia","volume":"19","author":"Alsufyani","year":"2021","journal-title":"Mol Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nri1604","article-title":"Mechanisms of Type-I- and Type-II-Interferon-Mediated Signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.02.002","article-title":"Dynamic Control of Type I IFN Signalling by an Integrated Network of Negative Regulators","volume":"36","author":"Porritt","year":"2015","journal-title":"Trends Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.9.4927","article-title":"IFN-\u03b1 Suppresses Activation of Nuclear Transcription Factors NF-\u03bab and Activator Protein 1 and Potentiates TNF-Induced Apoptosis","volume":"165","author":"Manna","year":"2000","journal-title":"J Immunol"},{"key":"B36","article-title":"IFN-Alpha Enhances TNF-Alpha-Induced Apoptosis Through Down-Regulation of C-Myc Protein Expression in HL-60 Cells","volume":"24","author":"Nakashima","year":"2005","journal-title":"J Exp Clin Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2011.0028","article-title":"The Role of Nuclear Factor \u03bab in the Interferon Response","volume":"31","author":"Pfeffer","year":"2011","journal-title":"J Interferon Cytokine Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4401219","article-title":"TNF Combined With IFN-Alpha Accelerates NF-kappaB-Mediated Apoptosis Through Enhancement of Fas Expression in Colon Cancer Cells","volume":"10","author":"Kimura","year":"2003","journal-title":"Cell Death Differ"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4401829","article-title":"Defining the Mechanism by Which IFN-\u03b2 Dowregulates C-Myc Expression in Human Melanoma Cells: Pivotal Role for Human Polynucleotide Phosphorylase (Hpnpaseold-35)","volume":"13","author":"Sarkar","year":"2006","journal-title":"Cell Death Differ"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0607830103","article-title":"RIG-G as a Key Mediator of the Antiproliferative Activity of Interferon-Related Pathways Through Enhancing P21 and P27 Proteins","volume":"103","author":"Xiao","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206139","article-title":"Interferon-Alpha Sensitizes Human Hepatoma Cells to TRAIL-Induced Apoptosis Through DR5 Upregulation and NF-Kappa B Inactivation","volume":"22","author":"Shigeno","year":"2003","journal-title":"Oncogene"},{"key":"B42","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41467-017-00573-w","article-title":"Signalling Strength Determines Proapoptotic Functions of STING","volume":"8","author":"Gulen","year":"2017","journal-title":"Nat Commun"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1717190115","article-title":"PUMA Amplifies Necroptosis Signaling by Activating Cytosolic DNA Sensors","volume":"115","author":"Chen","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-019-09073-z","article-title":"The Emerging Role of STING-Dependent Signaling on Cell Death","volume":"67","author":"Sun","year":"2019","journal-title":"Immunol Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120231","article-title":"Interferon-Stimulated Genes: A Complex Web of Host Defenses","volume":"32","author":"Schneider","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.05.023","article-title":"STING Pathway Activation Stimulates Potent Immunity Against Acute Myeloid Leukemia","volume":"15","author":"Curran","year":"2016","journal-title":"Cell Rep"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1038\/s41467-018-05315-0","article-title":"Interferon Gene Therapy Reprograms the Leukemia Microenvironment Inducing Protective Immunity to Multiple Tumor Antigens","volume":"9","author":"Escobar","year":"2018","journal-title":"Nat Commun"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.21749","article-title":"Interferon-Alpha Delays S-Phase Progression in Human Hepatocellular Carcinoma Cells via Inhibition of Specific Cyclin-Dependent Kinases","volume":"33","author":"Murphy","year":"2001","journal-title":"Hepatology"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000077133","article-title":"Effects of Interferon-\u03b1 on Cell Cycle Regulatory Proteins in Leukemic Cells","volume":"44","author":"Szeps","year":"2003","journal-title":"Leukemia Lymphoma"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181ad4092","article-title":"IRF9 Is a Key Factor for Eliciting the Antiproliferative Activity of IFN-Alpha","volume":"32","author":"Tsuno","year":"2009","journal-title":"J Immunother"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1089\/107999003772084860","article-title":"Novel Growth and Death Related Interferon-Stimulated Genes (ISGs) in Melanoma: Greater Potency of IFN-Beta Compared With IFN-Alpha2","volume":"23","author":"Leaman","year":"2003","journal-title":"J Interferon Cytokine Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-018-0011-2","article-title":"Interferons \u03b1 and \u03b2 in Cancer: Therapeutic Opportunities From New Insights","volume":"18","author":"Borden","year":"2019","journal-title":"Nat Rev Drug Discovery"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2020.1766865","article-title":"Increased Circulating Basic Fibroblast Growth Factor Levels in Acute Myeloid Leukemia: A Meta-Analysis","volume":"25","author":"Song","year":"2020","journal-title":"Hematology"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-336685","article-title":"Combination of Pegylated IFN-\u03b12b With Imatinib Increases Molecular Response Rates in Patients With Low- or Intermediate-Risk Chronic Myeloid Leukemia","volume":"118","author":"Simonsson","year":"2011","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.01.010","article-title":"Interferon Decreases VEGF Levels in Patients With Chronic Myeloid Leukemia Treated With Imatinib","volume":"38","author":"Legros","year":"2014","journal-title":"Leukemia Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.6.437","article-title":"Effects of Interferon Alpha on Vascular Endothelial Growth Factor Gene Transcription and Tumor Angiogenesis","volume":"95","author":"von Marschall","year":"2003","journal-title":"JNCI: J Natl Cancer Institute"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.09.006","article-title":"Dendritic Cells and Cancer Immunity","volume":"37","author":"Gardner","year":"2016","journal-title":"Trends Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00483","article-title":"Type I Interferons as Stimulators of DC-Mediated Cross-Priming: Impact on Anti-Tumor Response","volume":"4","author":"Schiavoni","year":"2013","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1101313","article-title":"Type I IFN Drives a Distinctive Dendritic Cell Maturation Phenotype That Allows Continued Class II MHC Synthesis and Antigen Processing","volume":"188","author":"Simmons","year":"2012","journal-title":"J Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00313","article-title":"The Impact of the Interferon\/TNF-Related Apoptosis-Inducing Ligand Signaling Axis on Disease Progression in Respiratory Viral Infection and Beyond","volume":"8","author":"Peteranderl","year":"2017","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa064","article-title":"IFN-\u03b1 Suppresses Myeloid Cytokine Production, Impairing IL-12 Production and the Ability to Support T-Cell Proliferation","volume":"222","author":"Mehrotra","year":"2020","journal-title":"J Infect Dis"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2009.05.005","article-title":"Types I and II Interferons Upregulate the Costimulatory CD80 Molecule in Monocytes via Interferon Regulatory Factor-1","volume":"78","author":"Bauvois","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65373-4","article-title":"Interferon (IFN)-Beta Gene Transfer Into TS\/A Adenocarcinoma Cells and Comparison With IFN-Alpha: Differential Effects on Tumorigenicity and Host Response","volume":"154","author":"Rozera","year":"1999","journal-title":"Am J Pathol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.2907","article-title":"Acute Myeloid Leukemia (AML): Different Treatment Strategies Versus a Common Standard Arm\u2013Combined Prospective Analysis by the German AML Intergroup","volume":"30","author":"B\u00fcchner","year":"2012","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22496","article-title":"A Comparison of Low-Dose Cytarabine and Hydroxyurea With or Without All-Trans Retinoic Acid for Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome in Patients Not Considered Fit for Intensive Treatment","volume":"109","author":"Burnett","year":"2007","journal-title":"Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline Dose Intensification in Acute Myeloid Leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"N Engl J Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0901409","article-title":"High-Dose Daunorubicin in Older Patients With Acute Myeloid Leukemia","volume":"361","author":"L\u00f6wenberg","year":"2009","journal-title":"New Engl J Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S1470-2045(13)70546-1","article-title":"Cancer Survival in Europe 1999-2007 by Country and Age: Results of EUROCARE\u20135-A Population-Based Study","volume":"15","author":"De Angelis","year":"2014","journal-title":"Lancet Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/Measurable Residual Disease in AML: A Consensus Document From the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01230-4","article-title":"Measurable Residual Disease as a Biomarker in Acute Myeloid Leukemia: Theoretical and Practical Considerations","volume":"35","author":"Walter","year":"2021","journal-title":"Leukemia"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.113","article-title":"Measurable Residual Disease Testing in Acute Myeloid Leukaemia","volume":"31","author":"Hourigan","year":"2017","journal-title":"Leukemia"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-577593","article-title":"Defining Minimal Residual Disease in Acute Myeloid Leukemia: Which Platforms are Ready for \"Prime Time\"","volume":"124","author":"Grimwade","year":"2014","journal-title":"Blood"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08595.x","article-title":"Review of the Relevance of Aberrant Antigen Expression by Flow Cytometry in Myeloid Neoplasms","volume":"153","author":"Ossenkoppele","year":"2011","journal-title":"Br J Haematol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-017-0414-2","article-title":"The Dynamics of RUNX1-RUNX1T1 Transcript Levels After Allogeneic Hematopoietic Stem Cell Transplantation Predict Relapse in Patients With T (8,21) Acute Myeloid Leukemia","volume":"10","author":"Qin","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-563403","article-title":"In Adults With T(8;21)AML, Posttransplant RUNX1\/RUNX1T1-Based MRD Monitoring, Rather Than C-KIT Mutations, Allows Further Risk Stratification","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/nature07815","article-title":"IFNalpha Activates Dormant Haematopoietic Stem Cells In Vivo","volume":"458","author":"Essers","year":"2009","journal-title":"Nature"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0692","article-title":"Interferon-\u03b1 Is Effective for Treatment of Minimal Residual Disease in Patients With T(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study","volume":"23","author":"Mo","year":"2018","journal-title":"Oncologist"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.04.023","article-title":"IFN-A Is Effective for Treatment of Minimal Residual Disease in Patients With Acute Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Registry Study","volume":"23","author":"Mo","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2021.1948027","article-title":"Interferon-\u03b1 as Maintenance Therapy can Significantly Reduce Relapse in Patients With Favorable-Risk Acute Myeloid Leukemia","author":"Jiang","year":"2021","journal-title":"Leukemia Lymphoma"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.078","article-title":"A Phase I\/II Clinical Trial of Type 1 Interferon for Reduction of Relapse After HCT in High Risk AML","volume":"25","author":"Magenau","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128505","article-title":"Interferon-A-2b As a Maintenance Therapy Significantly Improves Disease-Free Survival in Patients With Low-Risk Acute Myeloid Leukemia","volume":"134","author":"Liu","year":"2019","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2018.1527688","article-title":"A Comprehensive Review of Protein Kinase Inhibitors for Cancer Therapy","volume":"18","author":"Kannaiyan","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1126\/science.1062538","article-title":"Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26187","article-title":"Modelling Ponatinib Resistance in Tyrosine Kinase Inhibitor-Na\u00efve and Dasatinib Resistant BCR-ABL1+ Cell Lines","volume":"9","author":"Lu","year":"2018","journal-title":"Oncotarget"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-114-7-532","article-title":"Interferon-Alpha Produces Sustained Cytogenetic Responses in Chronic Myelogenous Leukemia. Philadelphia Chromosome-Positive Patients","volume":"114","author":"Talpaz","year":"1991","journal-title":"Ann Intern Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2007.06.015","article-title":"The Role of Interferon-Alpha in the Treatment of Chronic Myeloid Leukemia","volume":"18","author":"Kujawski","year":"2007","journal-title":"Cytokine Growth Factor Rev"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867","article-title":"Five-Year Follow-Up of Patients Receiving Imatinib for Chronic Myeloid Leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"New Engl J Med"},{"key":"B88","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib Compared With Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"New Engl J Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) Targets an Earlier Progenitor Population Than Imatinib in Primary CML But Does Not Eliminate the Quiescent Fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, Quiescent, Philadelphia-Positive Stem Cells From Patients With Chronic Myeloid Leukemia Are Insensitive to STI571 In Vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.021246","article-title":"The Response to Imatinib and Interferon-Alpha Is More Rapid Than the Response to Imatinib Alone: A Retrospective Analysis of 495 Philadelphia-Positive Chronic Myeloid Leukemia Patients in Early Chronic Phase","volume":"95","author":"Palandri","year":"2010","journal-title":"Haematologica"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.5075","article-title":"Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia","volume":"28","author":"Burchert","year":"2010","journal-title":"J Clin Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib Plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N Engl J Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.85","article-title":"Early Molecular and Cytogenetic Response Is Predictive for Long-Term Progression-Free and Overall Survival in Chronic Myeloid Leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of Imatinib as First-Line Treatment of Chronic Myeloid Leukemia: 10-Year Survival Results of the Randomized CML Study IV and Impact of Non-CML Determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.121","article-title":"Safety and Efficacy of the Combination of Pegylated Interferon-\u03b12b and Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients","volume":"30","author":"Hjorth-Hansen","year":"2016","journal-title":"Leukemia"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(14)00027-1","article-title":"Nilotinib and Peginterferon Alfa-2a for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukaemia (NiloPeg): A Multicentre, Non-Randomised, Open-Label Phase 2 Study","volume":"2","author":"Nicolini","year":"2015","journal-title":"Lancet Haematol"},{"key":"B98","unstructured":"HochhausA\n          TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study (TIGER) Clinicaltrials.Gov20122021"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating Interleukin (IL)-8, IL-2r, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00281-018-0700-2","article-title":"Perspectives on Interferon-Alpha in the Treatment of Polycythemia Vera and Related Myeloproliferative Neoplasms: Minimal Residual Disease and Cure","volume":"41","author":"Hasselbalch","year":"2019","journal-title":"Semin Immunopathol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120602","article-title":"Increased Expression of Interferon Signaling Genes in the Bone Marrow Microenvironment of Myelodysplastic Syndromes","volume":"10","author":"Kim","year":"2015","journal-title":"PloS One"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.269","article-title":"JAK Inhibitor Therapy for Myelofibrosis: Critical Assessment of Value and Limitations","volume":"25","author":"Pardanani","year":"2011","journal-title":"Leukemia"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb03306.x","article-title":"Long-Term Treatment With Interferon-Alpha 2b for Severe Pruritus in Patients With Polycythaemia Vera","volume":"89","author":"Muller","year":"1995","journal-title":"Br J Haematol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199802000-00024","article-title":"Busulfan Versus Hydroxyurea in the Treatment of Polycythemia Vera (PV) and Essential Thrombocythemia (ET)","volume":"21","author":"Brodsky","year":"1998","journal-title":"Am J Clin Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-258772","article-title":"The Renaissance of Interferon Therapy for the Treatment of Myeloid Malignancies","volume":"117","author":"Kiladjian","year":"2011","journal-title":"Blood"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.280","article-title":"Interferon-Alpha Therapy in Bcr-Abl-Negative Myeloproliferative Neoplasms","volume":"22","author":"Kiladjian","year":"2008","journal-title":"Leukemia"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3917","article-title":"Minimal Molecular Response in Polycythemia Vera Patients Treated With Imatinib or Interferon Alpha","volume":"107","author":"Jones","year":"2006","journal-title":"Blood"},{"key":"B109","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1182\/blood-2012-07-442012","article-title":"Molecular Analysis of Patients With Polycythemia Vera or Essential Thrombocythemia Receiving Pegylated Interferon \u03b1-2a","volume":"122","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Blood"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000428","article-title":"Pegylated Interferon Alfa-2a for Polycythemia Vera or Essential Thrombocythemia Resistant or Intolerant to Hydroxyurea","volume":"134","author":"Yacoub","year":"2019","journal-title":"Blood"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon Alfa-2b Versus Standard Therapy for Polycythaemia Vera (PROUD-PV and CONTINUATION-PV): A Randomised, Non-Inferiority, Phase 3 Trial and Its Extension Study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2018.1484280","article-title":"Diagnosis and Management of Prefibrotic Myelofibrosis","volume":"11","author":"Rumi","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25230","article-title":"Primary Myelofibrosis: 2019 Update on Diagnosis, Risk-Stratification and Management","volume":"93","author":"Tefferi","year":"2018","journal-title":"Am J Hematol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1619","article-title":"Safety and Efficacy of Combination Therapy of Interferon-\u03b12 and Ruxolitinib in Polycythemia Vera and Myelofibrosis","volume":"7","author":"Mikkelsen","year":"2018","journal-title":"Cancer Med"},{"key":"B115","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea Compared With Anagrelide in High-Risk Essential Thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide Compared With Hydroxyurea in WHO-Classified Essential Thrombocythemia: The ANAHYDRET Study, a Randomized Controlled Trial","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11486","article-title":"Phase II Study of Alpha2 Interferon in the Treatment of the Chronic Myeloproliferative Disorders (E5487): A Trial of the Eastern Cooperative Oncology Group","volume":"98","author":"Radin","year":"2003","journal-title":"Cancer"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400931","article-title":"Alfa-Interferon in the Treatment of Essential Thrombocythemia: Clinical Results and Evaluation of Its Biological Effects on the Hematopoietic Neoplastic Clone","volume":"12","author":"Sacchi","year":"1998","journal-title":"Ital Cooperative Group ET Leukemia"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-114744","article-title":"Differential Impact of Interferon Alpha on JAK2V617F and Calr Mutated Hematopoietic Stem and Progenitor Cells in Classical MPN","volume":"132","author":"Mosca","year":"2018","journal-title":"Blood"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-432989","article-title":"Depletion of Jak2V617F Myeloproliferative Neoplasm-Propagating Stem Cells by Interferon-\u03b1 in a Murine Model of Polycythemia Vera","volume":"121","author":"Mullally","year":"2013","journal-title":"Blood"},{"key":"B121","doi-asserted-by":"publisher","first-page":"5255","DOI":"10.1038\/s41598-021-83895-6","article-title":"Distinct Effects of V617F and Exon12-Mutated JAK2 Expressions on Erythropoiesis in a Human Induced Pluripotent Stem Cell (iPSC)-Based Model","volume":"11","author":"Nilsri","year":"2021","journal-title":"Sci Rep"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-005-1319-7","article-title":"Side Effects of Interferon-Alpha Therapy","volume":"27","author":"Sleijfer","year":"2005","journal-title":"Pharm World Sci"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1586\/eri.09.70","article-title":"Pegylated IFN-Alpha2a and Ribavirin in the Treatment of Hepatitis C","volume":"7","author":"Aghemo","year":"2009","journal-title":"Expert Rev Anti Infect Ther"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826050-00007","article-title":"Updated Estimates of Survival and Cost Effectiveness for Imatinib Versus Interferon-Alpha Plus Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukaemia","volume":"26","author":"Reed","year":"2008","journal-title":"Pharmacoeconomics"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.769628\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T06:31:29Z","timestamp":1635489089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.769628\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,29]]},"references-count":124,"alternative-id":["10.3389\/fonc.2021.769628"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.769628","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,29]]},"article-number":"769628"}}